BioNTech SE
BNTX
$99.47
$2.012.06%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 3.30B | 2.91B | 2.95B | 4.12B | 6.90B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.30B | 2.91B | 2.95B | 4.12B | 6.90B |
| Cost of Revenue | 518.02M | 497.44M | 610.40M | 649.19M | 643.87M |
| Gross Profit | 2.78B | 2.41B | 2.34B | 3.47B | 6.25B |
| SG&A Expenses | 643.31M | 644.93M | 597.20M | 586.23M | 587.58M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 653.55M | 307.47M | 6.31M | -43.98M | -258.65M |
| Total Operating Expenses | 4.22B | 3.79B | 3.34B | 3.12B | 2.80B |
| Operating Income | -919.13M | -885.07M | -382.34M | 998.68M | 4.10B |
| Income Before Tax | -339.05M | -266.01M | 152.62M | 1.27B | 3.80B |
| Income Tax Expenses | 161.73M | 277.75M | 34.17M | 272.68M | 965.00M |
| Earnings from Continuing Operations | -500.78 | -543.77 | 118.45 | 999.08 | 2.83K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -500.78M | -543.77M | 118.45M | 999.08M | 2.83B |
| EBIT | -919.13M | -885.07M | -382.34M | 998.68M | 4.10B |
| EBITDA | -738.86M | -708.66M | -224.92M | 1.15B | 4.23B |
| EPS Basic | -2.08 | -2.25 | 0.50 | 4.15 | 11.67 |
| Normalized Basic EPS | -0.56 | -0.47 | 0.57 | 3.43 | 9.83 |
| EPS Diluted | -2.11 | -2.28 | 0.48 | 4.10 | 11.52 |
| Normalized Diluted EPS | -0.57 | -0.49 | 0.55 | 3.39 | 9.69 |
| Average Basic Shares Outstanding | 962.27M | 960.39M | 960.99M | 963.06M | 966.25M |
| Average Diluted Shares Outstanding | 966.52M | 965.28M | 965.88M | 970.32M | 975.40M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
